CryoLife, Inc. (NYSE:CRY) – Equities researchers at First Analysis issued their Q3 2018 earnings per share estimates for shares of CryoLife in a research note issued to investors on Tuesday. First Analysis analyst anticipates that the medical equipment provider will post earnings per share of $0.02 for the quarter.

CryoLife (NYSE:CRY) last posted its earnings results on Monday, October 30th. The medical equipment provider reported $0.08 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.08. CryoLife had a net margin of 5.28% and a return on equity of 6.43%. The firm had revenue of $44.00 million for the quarter, compared to analyst estimates of $44.60 million. During the same period in the previous year, the firm posted $0.13 EPS. The company’s revenue for the quarter was down 2.9% compared to the same quarter last year.

COPYRIGHT VIOLATION WARNING: “CryoLife, Inc. Expected to Earn Q3 2018 Earnings of $0.02 Per Share (CRY)” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.thecerbatgem.com/2017/11/19/cryolife-inc-expected-to-earn-q3-2018-earnings-of-0-02-per-share-cry.html.

A number of other equities research analysts have also weighed in on the stock. Lake Street Capital boosted their target price on shares of CryoLife to $26.00 and gave the stock a “buy” rating in a report on Wednesday, October 11th. TheStreet lowered shares of CryoLife from a “b” rating to a “c+” rating in a report on Monday, October 30th. Zacks Investment Research lowered shares of CryoLife from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. BidaskClub lowered shares of CryoLife from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $25.00 price objective on shares of CryoLife in a research note on Monday, October 9th. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $23.63.

Shares of CryoLife (NYSE:CRY) opened at $19.20 on Friday. CryoLife has a 1-year low of $14.02 and a 1-year high of $24.00. The company has a current ratio of 5.96, a quick ratio of 4.90 and a debt-to-equity ratio of 0.29. The firm has a market cap of $642.39, a P/E ratio of 46.83 and a beta of 0.82.

In other news, CEO James P. Mackin sold 125,000 shares of the company’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $22.01, for a total value of $2,751,250.00. Following the sale, the chief executive officer now directly owns 398,399 shares of the company’s stock, valued at approximately $8,768,761.99. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP David C. Gale sold 20,000 shares of the company’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $19.63, for a total transaction of $392,600.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 229,240 shares of company stock worth $4,888,065. Insiders own 6.00% of the company’s stock.

Large investors have recently bought and sold shares of the company. State of Alaska Department of Revenue boosted its stake in shares of CryoLife by 80.8% in the 2nd quarter. State of Alaska Department of Revenue now owns 5,387 shares of the medical equipment provider’s stock valued at $107,000 after purchasing an additional 2,407 shares during the last quarter. First Mercantile Trust Co. boosted its stake in shares of CryoLife by 5.6% in the 2nd quarter. First Mercantile Trust Co. now owns 5,448 shares of the medical equipment provider’s stock valued at $109,000 after purchasing an additional 291 shares during the last quarter. Municipal Employees Retirement System of Michigan boosted its stake in shares of CryoLife by 3.7% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 6,380 shares of the medical equipment provider’s stock valued at $127,000 after purchasing an additional 230 shares during the last quarter. Creative Planning boosted its stake in shares of CryoLife by 3.0% in the 2nd quarter. Creative Planning now owns 6,806 shares of the medical equipment provider’s stock valued at $136,000 after purchasing an additional 200 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its position in shares of CryoLife by 17.7% during the 2nd quarter. Victory Capital Management Inc. now owns 6,937 shares of the medical equipment provider’s stock valued at $138,000 after acquiring an additional 1,041 shares during the period. 70.34% of the stock is currently owned by institutional investors.

About CryoLife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Earnings History and Estimates for CryoLife (NYSE:CRY)

Receive News & Stock Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related stocks with our FREE daily email newsletter.